Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 15/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 14/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.44 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4202830 | 0.87 | ITGAV (0.54) | ITGAVITGB3CXCR4ITGA2BITGB6 | |
| SCHEMBL8347928 | 0.84 | ITGAV (0.58) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL5797120 | 0.83 | ITGAV (0.60) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL17637776 | 0.83 | ITGAV (0.50) | ITGAVITGB3CXCR4ITGA2BITGB6 | |
| SCHEMBL12895016 | 0.83 | ITGAV (0.47) | ITGAVITGB3CXCR4ITGA2BITGB6 | |
| SCHEMBL326631 | 0.83 | ITGB3 (0.47) | ITGAVITGB3CXCR4ITGA2BITGB6 | |
| SCHEMBL317838 | 0.83 | ITGAV (0.47) | ITGAVITGB3CXCR4ITGA2BITGB6 | |
| SCHEMBL21784996 | 0.82 | ITGAV (0.59) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| Hydrochloric Acid SCHEMBL31125523 | 0.82 | ITGAV (0.59) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL4714404 | 0.81 | ITGB3 (0.52) | ITGAVITGB3CXCR4ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | claimed |
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-20200291017-A1 | CITRATE SALT OF THE COMPOUND (S)-4-((S)-3-FLUORO-3-(2-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYDRIN-2-YL)ETHYL)PYRROLIDIN-1-YL)-3-(3-(2-METHOXYETHOXY)PHENYL) BUTANOIC ACID | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200291017-A1 | CITRATE SALT OF THE COMPOUND (S)-4-((S)-3-FLUORO-3-(2-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYDRIN-2-YL)ETHYL)PYRROLIDIN-1-YL)-3-(3-(2-METHOXYETHOXY)PHENYL) BUTANOIC ACID | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20190275016-A1 | NOVEL COMPOUNDS avB6 INTEGRIN ANTAGONISTS. | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-20190275016-A1 | NOVEL COMPOUNDS avB6 INTEGRIN ANTAGONISTS. | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-10342783-B2 | Compounds αvβ6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-09 | — | — | US | disclosed |
| US-10342783-B2 | Compounds αvβ6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-09 | — | — | US | disclosed |
| EP-3433255-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-7119098-B2 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-6933304-B2 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1289983-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-09-19 | — | — | US | disclosed |
| WO-2001096334-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, ITGB3 | ITGAV 9/4885ITGB3 3/4885CXCR4 648/4885 |
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | ITGA5, ITGA2B, ITGAV | ITGAV 3/4885ITGB3 5/4885CXCR4 496/4885 |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | ITGA5, ITGB7, ITGA2B | ITGAV 13/4885ITGB3 5/4885CXCR4 573/4885 |
| US-20190275016-A1 | NOVEL COMPOUNDS avB6 INTEGRIN ANTAGONISTS. | ITGB6, ITGA6, GP6 | ITGAV 10/4885ITGB3 9/4885CXCR4 887/4885 |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | ITGAV 6/4885ITGB3 3/4885CXCR4 461/4885 |
| US-10342783-B2 | Compounds αvβ6 integrin antagonists | ITGA6, ITGB6, GP6 | ITGAV 4/4885ITGB3 9/4885CXCR4 986/4885 |
| US-20200291017-A1 | CITRATE SALT OF THE COMPOUND (S)-4-((S)-3-FLUORO-3-(2-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYDRIN-2-YL)ETHYL)PYRROLIDIN-1-YL)-3-(3-(2-METHOXYETHOXY)PHENYL) BUTANOIC ACID | IL36G, VCAM1, CS | ITGAV 7/4885ITGB3 9/4885CXCR4 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.